Illumina (ILMN) Upgraded to Buy at BidaskClub
BidaskClub upgraded shares of Illumina (NASDAQ:ILMN) from a hold rating to a buy rating in a report issued on Friday morning.
Several other equities research analysts also recently issued reports on the company. Leerink Swann restated an outperform rating and issued a $225.00 price target (up from $207.00) on shares of Illumina in a report on Tuesday, September 12th. Piper Jaffray Companies restated an overweight rating and issued a $226.00 price target (up from $202.00) on shares of Illumina in a report on Monday, October 9th. Wells Fargo & Co upgraded Illumina from a market perform rating to an outperform rating and set a $205.00 price target for the company in a report on Tuesday. Morgan Stanley increased their price target on Illumina from $122.00 to $135.00 and gave the stock an underweight rating in a report on Thursday, December 14th. Finally, Citigroup increased their price target on Illumina from $180.00 to $220.00 and gave the stock a neutral rating in a report on Wednesday, October 25th. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating and fifteen have assigned a buy rating to the stock. The company presently has a consensus rating of Buy and an average price target of $207.74.
Shares of Illumina (NASDAQ:ILMN) traded down $4.82 during trading on Friday, hitting $228.17. The company’s stock had a trading volume of 1,456,897 shares, compared to its average volume of 667,293. Illumina has a 12 month low of $132.02 and a 12 month high of $233.54. The company has a market capitalization of $34,016.54, a P/E ratio of 42.73, a P/E/G ratio of 3.19 and a beta of 0.79. The company has a quick ratio of 3.73, a current ratio of 4.22 and a debt-to-equity ratio of 0.41.
Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Tuesday, October 24th. The life sciences company reported $1.11 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.99 by $0.12. Illumina had a return on equity of 19.42% and a net margin of 30.34%. The company had revenue of $714.00 million during the quarter, compared to the consensus estimate of $692.77 million. During the same period in the prior year, the company earned $0.97 earnings per share. The company’s revenue for the quarter was up 17.6% compared to the same quarter last year. equities research analysts expect that Illumina will post 3.75 EPS for the current fiscal year.
In other news, Director Jay T. Flatley sold 20,000 shares of the firm’s stock in a transaction that occurred on Tuesday, October 10th. The stock was sold at an average price of $203.27, for a total value of $4,065,400.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Marc Stapley sold 2,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 15th. The shares were sold at an average price of $205.48, for a total value of $410,960.00. Following the completion of the sale, the executive vice president now directly owns 30,370 shares of the company’s stock, valued at $6,240,427.60. The disclosure for this sale can be found here. Insiders have sold 158,921 shares of company stock valued at $33,810,181 over the last three months. Insiders own 0.89% of the company’s stock.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Private Asset Management Inc. lifted its position in shares of Illumina by 2.2% in the fourth quarter. Private Asset Management Inc. now owns 11,072 shares of the life sciences company’s stock valued at $2,419,000 after buying an additional 240 shares during the last quarter. Parametric Portfolio Associates LLC lifted its position in shares of Illumina by 41.2% in the third quarter. Parametric Portfolio Associates LLC now owns 290,458 shares of the life sciences company’s stock valued at $57,859,000 after buying an additional 84,690 shares during the last quarter. Moors & Cabot Inc. lifted its position in shares of Illumina by 7.1% in the third quarter. Moors & Cabot Inc. now owns 7,500 shares of the life sciences company’s stock valued at $1,497,000 after buying an additional 500 shares during the last quarter. IFM Investors Pty Ltd acquired a new stake in shares of Illumina in the third quarter valued at approximately $804,000. Finally, DF Dent & Co. Inc. lifted its position in shares of Illumina by 4.0% in the third quarter. DF Dent & Co. Inc. now owns 486,530 shares of the life sciences company’s stock valued at $96,917,000 after buying an additional 18,741 shares during the last quarter. 91.60% of the stock is owned by institutional investors.
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with Analyst Ratings Network's FREE daily email newsletter.